$5.13
0.37[7.77%]
At close: Apr 17
$5.13
0[0.00%]
After Hours: 7:47PM EDT
Lipocine
(NASDAQ:LPCN)Latest News for Lipocine Stock (NASDAQ:LPCN)
Lipocine Stock (NASDAQ: LPCN)
Categories: All
Thursday, April 11, 2024
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - 6 days ago
- Lipocine shares are trading higher after the company announced trial data showing LPCN 2401 treatment resulted in statistically significant body composition improvement in men.Benzinga Newsdesk - 6 days ago
- Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related ComorbidityBenzinga Newsdesk - 6 days ago
Thursday, March 28, 2024
Monday, March 25, 2024
Wednesday, March 13, 2024
Tuesday, February 06, 2024
Thursday, January 18, 2024
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Jan 18, 2024, 8:05AM
- Lipocine And Verity Pharma Enter Into License Agreement For TLANDO Franchise In The U.S. And Canada; Lipocine To Receive $11M License Fee; Up To $259M In Development And Commercial Sales MilestonesBenzinga Newsdesk - Jan 18, 2024, 8:03AM
Monday, November 13, 2023
Friday, October 06, 2023
Thursday, September 28, 2023
Wednesday, August 16, 2023
Thursday, August 10, 2023
Thursday, July 27, 2023
- Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Jul 27, 2023, 12:53PM
- Why Lipocine Stock Is Moving Higher Today?Vandana Singh - Jul 27, 2023, 12:22PM
- Cantor Fitzgerald Reiterates Overweight on Lipocine, Maintains $33 Price TargetBenzinga Newsdesk - Jul 27, 2023, 10:09AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Jul 27, 2023, 9:05AM
- Market-Moving News for July 27thBenzinga Newsdesk - Jul 27, 2023, 8:34AM
- Lipocine shares are trading higher after the company reported LPCN 1148 Phase 2 Study met its primary endpoint in patients with cirrhosis.Benzinga Newsdesk - Jul 27, 2023, 6:48AM
- Lipocine Announced Topline Results From A Phase 2 Study Of LPCN 1148, For The Clinical Management Of Cirrhosis, Meeting The Primary Endpoint With The Treatment With LPCN 1148 Increased L3 Skeletal Muscle Index Relative To PlaceboBenzinga Newsdesk - Jul 27, 2023, 6:35AM
Tuesday, May 16, 2023
- Stocks That Hit 52-Week Lows On TuesdayBenzinga Insights - May 16, 2023, 1:01PM
- Lipocine Announced Topline Results From A Pilot Clinical PK Bridge Study Of LPCN 1154 (Oral Brexanolone) With A Comparator, Iv Brexanolone, Demonstrating LPCN 1154 Treatment Was Well-tolerated With No Hypoxia Or Sedation-related Adverse EventsBenzinga Newsdesk - May 16, 2023, 7:15AM
Thursday, May 11, 2023
- Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - May 11, 2023, 1:46PM
- Lipocine Says On May 10 Board Approved 1-For-17 Reverse Stock Split, Effective May 12Benzinga Newsdesk - May 11, 2023, 12:49PM
- Recap: Lipocine Q1 EarningsBenzinga Insights - May 11, 2023, 8:25AM
- Lipocine Q1 EPS $(0.04) Misses $(0.02) Estimate, Sales $54.99K Miss $780.00K EstimateBenzinga Newsdesk - May 11, 2023, 6:08AM
Friday, May 05, 2023
Tuesday, April 04, 2023
Monday, March 27, 2023
Monday, March 20, 2023
Monday, March 13, 2023
Friday, March 10, 2023
- Stocks That Hit 52-Week Lows On FridayBenzinga Insights - Mar 10, 2023, 1:27PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Mar 10, 2023, 12:31PM
- Lipocine shares are trading lower after the company reported Q4 financial results.Michael Horton - Mar 10, 2023, 11:42AM
- CORRECTION: Lipocine Q4 EPS $(0.03), InlineHappy Mohamed - Mar 10, 2023, 8:38AM
- Lipocine Q4 EPS $(0.03), InlineHappy Mohamed - Mar 10, 2023, 8:32AM